These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4219758)

  • 1. Experiments with cholera toxin detoxified with glutaraldehyde.
    Saletti M; Ricci A
    Bull World Health Organ; 1974; 51(6):633-9. PubMed ID: 4219758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiments on monkeys with cholera toxin partially purified and detoxified with formol and glycine.
    Saletti M; Ricci A
    Bull World Health Organ; 1974; 51(6):641-5. PubMed ID: 4219759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a purified cholera toxoid. II. Preparation of a stable, antigenic toxoid by reaction of purified toxin with glutaraldehyde.
    Rappaport RS; Bonde G; McCann T; Rubin BA; Tint H
    Infect Immun; 1974 Feb; 9(2):304-17. PubMed ID: 4205946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on cholera toxin and antitoxin.
    Ungar J; Stanić M; Chariatte N; Varallyay SJ
    J Gen Microbiol; 1970 Nov; 64(1):1-10. PubMed ID: 5516606
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of cholera toxoid in an enzyme-linked immunosorbent assay for antitoxin.
    Cruce DD; Wachsmuth IK; Feeley JC
    Diagn Immunol; 1983; 1(2):87-9. PubMed ID: 6680095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholera toxin and toxoid.
    Ungar J; Stanić M; Chariatte N; Varallyay SJ
    Prog Immunobiol Stand; 1971; 5():348-9. PubMed ID: 4660540
    [No Abstract]   [Full Text] [Related]  

  • 7. Cholera toxin as a mucosal adjuvant. Glutaraldehyde treatment dissociates adjuvanticity from toxicity.
    Liang XP; Lamm ME; Nedrud JG
    J Immunol; 1989 Jul; 143(2):484-90. PubMed ID: 2544646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Procedure for the manufacture of vaccines by means of glutaraldehyde].
    Relyveld EH; Girard O; Désormeau-Bedot JP
    Ann Immunol Hung; 1973; 17():21-31. PubMed ID: 4218935
    [No Abstract]   [Full Text] [Related]  

  • 9. Further studies on the cholera toxin and antitoxin.
    Ungar J; Stanić M; Varallyay SJ; Chariatte N
    Prog Immunobiol Stand; 1970; 4():583-9. PubMed ID: 4099025
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen.
    Rappaport RS; Pierzchala WA; Bonde G; McCann T; Rubin BA
    Infect Immun; 1976 Sep; 14(3):687-93. PubMed ID: 823117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental studies on cholera immunization. II. Evidence for protective antitoxic immunity mediated by serum antibodies as well as local antibodies.
    Holmgren J; Andersson A; Wallerstrom G; Ouchterlony O
    Infect Immun; 1972 May; 5(5):662-7. PubMed ID: 4637602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids.
    Holmgren J; Lönnroth I; Svennerholm L
    Infect Immun; 1973 Aug; 8(2):208-14. PubMed ID: 4125267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MECHANISM OF THE POTENTIATION OF TOXOID ANTIGENIC ACTION BY MEANS OF TOXIN. I. SPECIFICITY OF THE POTENTIATING ACTION OF TOXIN].
    MORGUNOV IN; IAGUD SL; BARSHTEIN IuA
    Zh Mikrobiol Epidemiol Immunobiol; 1964 Apr; 41():40-5. PubMed ID: 14224707
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunity to cholera: relation of fraction II of type 2 cholera toxin to vibriocidal antibody.
    Kaur J; Burrows W
    J Bacteriol; 1969 May; 98(2):467-74. PubMed ID: 4977478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
    Svennerholm AM
    Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of potent antivenin against cobra venom with conjugated-cobrotoxin.
    Huang HC; Liau MY; Lee YC
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1979 Sep; 12(3):93-8. PubMed ID: 121068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocyte response to a purified bacterial toxin (choleragen) and toxoid: cytokinetics, immunoglobulin class, and specificity.
    Kateley JR; Lyons SF; Friedman H
    J Immunol; 1974 Apr; 112(4):1452-60. PubMed ID: 4592602
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion of cholera exo-enterotoxin (choleragen) to natural toxoid (choleragenoid).
    Finkelstein RA; Peterson JW; Lospalluto JJ
    J Immunol; 1971 Mar; 106(3):868-71. PubMed ID: 4993866
    [No Abstract]   [Full Text] [Related]  

  • 19. Response of monkeys to immunization with cholera toxoid, toxin, and vaccine: reversion of cholera toxoid.
    Northrup RS; Chisari FV
    J Infect Dis; 1972 May; 125(5):471-9. PubMed ID: 4623435
    [No Abstract]   [Full Text] [Related]  

  • 20. [A new process of inactivation for preparation of vaccines].
    Relyveld EH; Girard O; Cheyroux M; Asso J; de Rudder J
    Dev Biol Stand; 1974; 27():236-48. PubMed ID: 4218994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.